Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284

/PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform...

Related Keywords

Dallas ,Texas ,United States ,Kishor Bhatia ,Broad Institute ,National Cancer Institute ,Exchange Commission On ,Twitter ,National Institutes Of Health ,Drug Administration ,Society Of Neuro ,Developmental Therapeutics Branch ,Securities Exchange ,Lantern Pharma ,National Institutes ,Glioblastoma Multiforme ,Chief Scientific Officer ,Pharmacology Facility ,Project Achilles ,Panna Sharma ,Drug Designation ,Response Algorithm ,Drug Positioning ,Securities Act ,Securities Exchange Act ,Risk Factors ,Annual Report ,Exchange Commission ,